## Staging, Prognosis, and Management of Pancreatic Head Cancer **Key Point:** Pancreatic cancer management is multimodal and depends on resectability status. EUS-FNA is a safe, standard diagnostic tool—not a contraindication. ### TNM Staging and Resectability Assessment **High-Yield:** Pancreatic cancer staging integrates tumor size (T), nodal involvement (N), and metastatic status (M). Upstream duct dilatation in a head mass indicates locally advanced disease but does not preclude resection if vascular invasion is absent. | Feature | Resectable | Borderline Resectable | Locally Advanced (Unresectable) | |---|---|---|---| | **Vascular involvement** | None or minimal | Partial encasement of artery/vein | Encasement of major vessel (SMA, celiac trunk) | | **Distant metastases** | None | None | May be present | | **Prognosis** | 5-year OS ~20–25% post-resection | 5-year OS ~15–20% | 5-year OS <5% | ### Surgical Management **Clinical Pearl:** Whipple pancreaticoduodenectomy (WPDU) is the gold standard for resectable pancreatic head cancer. It involves en bloc resection of the pancreatic head, duodenum, common bile duct, and distal stomach, with reconstruction via pancreaticojejunostomy and hepaticojejunostomy. Morbidity is significant (~40% major complications), but it offers the only curative intent. ### Adjuvant Chemotherapy **Key Point:** The CONKO-001 and ESPAC-1 trials established that adjuvant gemcitabine improves disease-free and overall survival post-resection. Current standard is gemcitabine monotherapy or gemcitabine–cisplatin (NCCN guidelines). This patient, if resected, would be a candidate. ### Why EUS-FNA Is NOT Contraindicated **High-Yield:** EUS-FNA is the **preferred diagnostic modality** for pancreatic masses, especially in the head. It offers: - High sensitivity (~95%) and specificity for malignancy - Real-time ultrasound guidance under endoscopy - Low morbidity (pancreatitis <1%, bleeding <0.5%) - **No increased risk of tumor seeding or peritoneal dissemination** **Warning:** The myth that EUS-FNA causes tumor seeding is **unfounded** and contradicted by decades of clinical data. Tumor cells in the needle tract are rare and do not impact prognosis. This is a common misconception in medical education. **Mnemonic:** **SAFE-FNA** — Sensitive, Accurate, Feasible, Essential for diagnosis; Fine-Needle Aspiration is safe. ### Diagnostic Algorithm for Pancreatic Head Mass ```mermaid flowchart TD A[Pancreatic head mass on imaging]:::outcome --> B{Resectable?}:::decision B -->|Yes| C[EUS-FNA for tissue diagnosis]:::action C --> D[Staging CT/MRI + labs]:::action D --> E{Fit for surgery?}:::decision E -->|Yes| F[WPDU]:::action E -->|No| G[Neoadjuvant chemoradiation]:::action B -->|Borderline| H[Neoadjuvant chemotherapy]:::action B -->|Locally advanced| I[Palliative chemotherapy]:::action F --> J[Adjuvant gemcitabine-cisplatin]:::action J --> K[Surveillance]:::outcome ``` [cite:Harrison 21e Ch 297; NCCN Pancreatic Cancer Guidelines 2023]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.